---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-23-000081"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T01:29:06.301106+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Pfizer restructures R&D, elevates Oncology as standalone unit; CDO William Pao departing Aug 15

## Summary
- Pfizer restructures R&D, making Oncology a standalone unit; Dr. Chris Boshoff becomes Chief Oncology R&D Officer, EVP.
- Dr. William Pao, Chief Development Officer, EVP, role eliminated; he will depart effective August 15, 2023.
- Severance includes one year base salary and target bonus, two years welfare benefits, vesting of sign-on awards.
- Reorganization driven by planned investment in Oncology, including proposed acquisition of Seagen Inc.

## SEC filing metadata
- accession: 0000078003-23-000081
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/pfe-20230721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-23-000081
- JSON: https://secwatch.observer/filing/0000078003-23-000081.json
- Plain text: https://secwatch.observer/filing/0000078003-23-000081.txt

## Key facts
- Executive change
  William Pao departed as Chief Development Officer, Executive Vice President at PFIZER INC.
  - Action: departed
  - Role: Chief Development Officer, Executive Vice President
  source text: As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm
- Executive change
  Chris Boshoff was appointed as Chief Oncology Research and Development Officer, Executive Vice President at PFIZER INC.
  - Action: appointed
  - Role: Chief Oncology Research and Development Officer, Executive Vice President
  source text: Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.